Akrevia Therapeutics, rebranded as Xilio Therapeutics, has bagged $100.5 million to progress the organizational tumor-selective cytokine pipeline.
FREMONT, CA: A company developing potent, tumor-selective immuno-oncology (IO) therapies for patients with cancer, Xilio Therapeutics has raised $100.5 million Series B financing. This round was led by Takeda Ventures, Inc. with new investors such as Bay City Capital, MRL Ventures Fund, SV Health Investors, M Ventures, RiverVest Venture Partners, Solasta Ventures, and Ipsen Ventures. Existing investors, Atlas Venture and F-Prime Capital in the syndicate, also joined the round. The raised capital will progress Xilio’s first two therapeutic candidates, XTX101 (tumor-selective aCTLA4 mAb) and XTX201 (tumor-selective IL-2) through Investigational New Drug (IND). It will facilitate studies and Phase 1 clinical trials and advance additional tumor-selective cytokine programs using Xilio’s proprietary technology.
Xilio Therapeutics is developing its proprietary technology for creating modern ultra-potent IO therapies that are activated selectively within the tumor. Such tumor-selective therapies are designed to overcome significant toxicities associated with validated IO therapies, like IL-2 and aCTLA4. These validated IO therapies have historically restricted the number of patients who can be treated and prevented patients from completing entire courses of treatment. XTX101 (aCTLA4 mAb) and XTX201 (IL-2) have demonstrated tumor-selective activity in preclinical models, significantly widening the potential therapeutic index for these therapies. IO therapies have emerged as a major driver of cancer therapeutic development, and agents in this space have proven efficient, resulting in compelling durable clinical responses.
Xilio Therapeutics is a biotechnology organization advancing next-generation cancer immunotherapies designed to enhance patient outcomes by unleashing the potential of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its established technology, which maximizes the ability of proven immuno-oncology therapies and limits their activity to the tumor to reduce peripheral side effects. The extensive applicability of these therapies across cancer types indicates that all patients could benefit from these potentially curative medicines.